| Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. | |
| | |
MedLine Citation:
|
PMID: 20795946 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of the present study was to test the effect of sitagliptin and exendin-4 upon metabolic alterations, β-cell mass decrease and hepatic steatosis induced by F (fructose) in rats. Normal adult male Wistar rats received a standard commercial diet without (C) or with 10% (w/v) F in the drinking water (F) for 3 weeks; animals from each group were randomly divided into three subgroups: untreated (C and F) and simultaneously receiving either sitagliptin (CS and FS; 115.2 mg/day per rat) or exendin-4 (CE and FE; 0.35 nmol/kg of body weight, intraperitoneally). Water and food intake, oral glucose tolerance, plasma glucose, triacylglycerol (triglyceride), insulin and fructosamine concentration, HOMA-IR [HOMA (homoeostasis model assessment) for insulin resistance], HOMA-β (HOMA for β-cell function) and liver triacylglycerol content were measured. Pancreas immunomorphometric analyses were also performed. IGT (impaired glucose tolerance), plasma triacylglycerol, fructosamine and insulin levels, HOMA-IR and HOMA-β indexes, and liver triacylglycerol content were significantly higher in F rats. Islet β-cell mass was significantly lower in these rats, due to an increase in the percentage of apoptosis. The administration of exendin-4 and sitagliptin to F animals prevented the development of all the metabolic disturbances and the changes in β-cell mass and fatty liver. Thus these compounds, useful in treating Type 2 diabetes, would also prevent/delay the progression of early metabolic and tissue markers of this disease. |
| | |
Authors:
|
Bárbara Maiztegui; María I Borelli; Viviana G Madrid; Héctor Del Zotto; María A Raschia; Flavio Francini; María L Massa; Luis E Flores; Oscar R Rebolledo; Juan J Gagliardino |
Related Documents
:
|
6135416 - Interactions between insulin and thyroid hormone in the control of lipogenesis. 6362806 - Oxytocin resistance in brattleboro rat adipocytes and comparative studies on insulin or... 7108896 - Species- or isozyme-specific enzyme inhibitors. 6. synthesis and evaluation of two-subs... 6834056 - Regional cerebral glucose utilization in rats with portacaval anastomosis. 8883816 - Effects of an electrolytic lesion of the prelimbic area on anxiety-related and cognitiv... 3960386 - Lateralized and compulsive exteroceptive orientation in rats treated with apomorphine. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical science (London, England : 1979) Volume: 120 ISSN: 1470-8736 ISO Abbreviation: Clin. Sci. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-10-08 Completed Date: 2011-01-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7905731 Medline TA: Clin Sci (Lond) Country: England |
Other Details:
|
Languages: eng Pagination: 73-80 Citation Subset: IM |
Affiliation:
|
CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET LA PLATA, Centro Colaborador OPS/OMS), Facultad de Ciencias Médicas UNLP, La Plata, Argentina. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Apoptosis / drug effects Blood Glucose / metabolism Body Weight / drug effects Diet Dipeptidyl-Peptidase IV Inhibitors / therapeutic use* Drinking / drug effects Drug Evaluation, Preclinical / methods Eating / drug effects Fatty Liver / etiology, pathology, prevention & control* Fructose / administration & dosage Glucose Tolerance Test / methods Hypoglycemic Agents / therapeutic use Insulin-Secreting Cells / drug effects*, pathology Male Metabolic Syndrome X / pathology, prevention & control* Peptides / therapeutic use Pyrazines / therapeutic use* Rats Rats, Wistar Triazoles / therapeutic use* Venoms / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Dipeptidyl-Peptidase IV Inhibitors; 0/Hypoglycemic Agents; 0/Peptides; 0/Pyrazines; 0/Triazoles; 0/Venoms; 0/sitagliptin; 141732-76-5/exenatide; 30237-26-4/Fructose |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: AHR, a novel acute hypoxia-response sequence, drives reporter gene expression under hypoxia in vitro...
Next Document: Resistin contributes to neointimal formation via oxidative stress after vascular injury.